

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HARIHARAN *et al.*

Appl. No.: 10/530,951 (*U.S. National  
Phase of PCT Appl. No. PCT/US03/18253*)

I.A. Filing Date: June 10, 2003

For: **Genes Overexpressed By Ovarian  
Cancer and Their Use In  
Developing Novel Therapeutics**

Confirmation No.: 3427

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 2159.0620008/EKS/J-H

**Preliminary Amendment Under 37 C.F.R. § 1.115 and  
Submission of Sequence Listing**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

**Amendments to the Specification** begin on page 2 of this paper

**Remarks** begin on page 6 of this paper.